Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCL12 | P48061 | 2/20 | 0.52 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.48 |
| ▸ | XDH | P47989 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | CASP6 | P55212 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | ABL2 | P42684 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | TPMT | P51580 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4576554 | 1.00 | CXCL12 (0.52) | CXCL12MKNK2XDHNPC1RAB9A | |
| SCHEMBL4576720 | 0.85 | TTR (0.55) | CXCL12NPC1RAB9AMAPTPOLB | |
| SCHEMBL4576719 | 0.85 | TTR (0.55) | CXCL12NPC1RAB9AMAPTPOLB | |
| SCHEMBL5693344 | 0.83 | PKM (0.61) | CXCL12MKNK2XDHNPC1RAB9A | |
| SCHEMBL5693342 | 0.83 | PKM (0.61) | CXCL12MKNK2XDHNPC1RAB9A | |
| SCHEMBL4254456 | 0.81 | ABCG2 (0.67) | CXCL12NPC1RAB9AGAAMAPT | |
| SCHEMBL4254451 | 0.81 | ABCG2 (0.67) | CXCL12NPC1RAB9AGAAMAPT | |
| SCHEMBL918999 | 0.81 | TUBB1 (0.66) | MAPTTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL919000 | 0.81 | TUBB1 (0.66) | MAPTTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL918500 | 0.80 | AHR (0.68) | CXCL12MKNK2NPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255245-A1 | Anti-Inflammatory and Psoriasis Treatment and Protein Kinase Inhibition by Hydroxystilbenes and Novel Stilbene Derivatives and Analogues | WELICHEM BIOTECH INC. (CA) | 2008-10-16 | — | — | US | disclosed |
| US-7321050-B2 | Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues | WELICHEM BIOTECH INC. (CA) | 2008-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255245-A1 | Anti-Inflammatory and Psoriasis Treatment and Protein Kinase Inhibition by Hydroxystilbenes and Novel Stilbene Derivatives and Analogues | NFKBIA, IKBKB, IKBKE | CXCL12 2212/4885MKNK2 191/4885XDH 2220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.